Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Mise à jour : Il y a 4 ans
Référence : NCT00205478

Femme et Homme

Extrait

The purpose of this study is to assess the clinical activity and safety of two doses of VX-702 compared to placebo in subjects with moderate to severe Rheumatoid Arthritis.


Critère d'inclusion

  • Rheumatoid Arthritis


Liens